681 related articles for article (PubMed ID: 14565927)
1. MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation.
Gregers TF; Fleckenstein B; Vartdal F; Roepstorff P; Bakke O; Sandlie I
Int Immunol; 2003 Nov; 15(11):1291-9. PubMed ID: 14565927
[TBL] [Abstract][Full Text] [Related]
2. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
Carstens C; Newman DK; Bohlen H; König A; Koch N
Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
[TBL] [Abstract][Full Text] [Related]
3. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation.
Malcherek G; Wirblich C; Willcox N; Rammensee HG; Trowsdale J; Melms A
Eur J Immunol; 1998 May; 28(5):1524-33. PubMed ID: 9603457
[TBL] [Abstract][Full Text] [Related]
4. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.
Morkowski S; Goldrath AW; Eastman S; Ramachandra L; Freed DC; Whiteley P; Rudensky AYu
J Exp Med; 1995 Nov; 182(5):1403-13. PubMed ID: 7595211
[TBL] [Abstract][Full Text] [Related]
5. Effect of decreasing the affinity of the class II-associated invariant chain peptide on the MHC class II peptide repertoire in the presence or absence of H-2M.
Honey K; Forbush K; Jensen PE; Rudensky AY
J Immunol; 2004 Apr; 172(7):4142-50. PubMed ID: 15034026
[TBL] [Abstract][Full Text] [Related]
6. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
[TBL] [Abstract][Full Text] [Related]
7. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells.
Fujii S; Senju S; Chen YZ; Ando M; Matsushita S; Nishimura Y
Hum Immunol; 1998 Oct; 59(10):607-14. PubMed ID: 9757942
[TBL] [Abstract][Full Text] [Related]
8. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
9. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
10. Diversity of endogenous epitopes bound to MHC class II molecules limited by invariant chain.
Bodmer H; Viville S; Benoist C; Mathis D
Science; 1994 Mar; 263(5151):1284-6. PubMed ID: 7510069
[TBL] [Abstract][Full Text] [Related]
11. Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules.
Bangia N; Watts TH
Int Immunol; 1995 Oct; 7(10):1585-91. PubMed ID: 8562503
[TBL] [Abstract][Full Text] [Related]
12. The functional role of class II-associated invariant chain peptide (CLIP) in its ability to variably modulate immune responses.
Chaturvedi P; Hengeveld R; Zechel MA; Lee-Chan E; Singh B
Int Immunol; 2000 Jun; 12(6):757-65. PubMed ID: 10837403
[TBL] [Abstract][Full Text] [Related]
13. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
Thayer WP; Ignatowicz L; Weber DA; Jensen PE
J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
[TBL] [Abstract][Full Text] [Related]
14. N-terminal functional region of the invariant chain efficiently targets the binding of a CTL epitope to MHC class I molecules during cross-presentation.
Wu C; Zhang DG; Chen FF; Liu XL; Liu SJ; Yu WY
Genet Mol Res; 2014 Apr; 13(2):2438-50. PubMed ID: 24781998
[TBL] [Abstract][Full Text] [Related]
15. Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins.
Sanderson S; Frauwirth K; Shastri N
Proc Natl Acad Sci U S A; 1995 Aug; 92(16):7217-21. PubMed ID: 7638170
[TBL] [Abstract][Full Text] [Related]
16. Altered major histocompatibility complex class II peptide loading in H2-O-deficient mice.
Perraudeau M; Taylor PR; Stauss HJ; Lindstedt R; Bygrave AE; Pappin DJ; Ellmerich S; Whitten A; Rahman D; Canas B; Walport MJ; Botto M; Altmann DM
Eur J Immunol; 2000 Oct; 30(10):2871-80. PubMed ID: 11069069
[TBL] [Abstract][Full Text] [Related]
17. The MHC class II molecule I-Ag7 exists in alternate conformations that are peptide dependent.
Arneson LS; Peterson M; Sant AJ
J Immunol; 2000 Aug; 165(4):2059-67. PubMed ID: 10925290
[TBL] [Abstract][Full Text] [Related]
18. Single-chain MHC class II molecules induce T cell activation and apoptosis.
Rhode PR; Burkhardt M; Jiao J; Siddiqui AH; Huang GP; Wong HC
J Immunol; 1996 Dec; 157(11):4885-91. PubMed ID: 8943392
[TBL] [Abstract][Full Text] [Related]
19. A continuous central motif of invariant chain peptides, CLIP, is essential for binding to various I-A MHC class II molecules.
Weenink SM; Milburn PJ; Gautam AM
Int Immunol; 1997 Feb; 9(2):317-25. PubMed ID: 9040013
[TBL] [Abstract][Full Text] [Related]
20. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
